Anthera Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANTH research report →
About the company
Anthera Pharmaceuticals, Inc. , a biopharmaceutical enterprise, concentrates on developing and commercializing therapeutic solutions for conditions with significant unmet medical needs. The company's pipeline includes Sollpura, an investigational non-porcine pancreatic enzyme replacement therapy in Phase III clinical trials for individuals with exocrine pancreatic insufficiency.
- CEO
- Paul F. Truex
- IPO
- 2010
- Employees
- 21
- HQ
- Houston, TX, US
Price Chart
- Market Cap
- $26.18K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- 0.08
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -485.59%
- ROIC
- 3509.83%
- Revenue
- $0 · -100.00%
- Net Income
- $-16,935,000 · 68.41%
- EPS
- $-1.65 · 84.10%
- Op Income
- $-36,432,000
- FCF YoY
- 25.73%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -123.12
- Avg Volume
- 2.64K
Get TickerSpark's AI analysis on ANTH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 5, 18 | THOMPSON JOHN CRAIG | other | 1,847,074 |
| Jan 5, 18 | SHANAHAN WILLIAM R JR | other | 567,876 |
| Jan 5, 18 | TRUEX PAUL F | other | 84,705 |
| Jan 5, 18 | Thompson David E. | other | 84,705 |
| Jan 5, 18 | Sager Philip | other | 84,705 |
| Jan 5, 18 | Mueller Brian | other | 84,705 |
| Jan 5, 18 | Furse Brent | other | 84,705 |
| Jan 5, 18 | HENNEY CHRISTOPHER S | other | 84,705 |
| Sep 20, 17 | THOMPSON JOHN CRAIG | buy | 8,550 |
| Sep 7, 17 | TRUEX PAUL F | buy | 5,000 |
Our ANTH coverage
Recent articles, reports, and earnings notes.
No research on ANTH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ANTH report →Similar companies
Peers in the same neighborhood.